Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 8/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4523445 | 0.96 | NR1H4 (0.41) | HRH4NR1H4GAA | |
| SCHEMBL4520698 | 0.93 | NR1H4 (0.40) | NR1H4 | |
| SCHEMBL4527486 | 0.92 | NR1H4 (0.40) | NR1H4 | |
| SCHEMBL4519590 | 0.89 | NR1H4 (0.38) | NR1H4TLR9TLR8TLR7 | |
| SCHEMBL4525379 | 0.87 | NR1H4 (0.46) | NR1H4PARP1 | |
| SCHEMBL4528374 | 0.87 | NR1H4 (0.38) | NR1H4TLR9TLR8TLR7 | |
| SCHEMBL4531385 | 0.87 | CACNA2D1 (0.44) | NR1H4 | |
| SCHEMBL4526606 | 0.86 | NR1H4 (0.38) | HRH4NR1H4 | |
| SCHEMBL4525870 | 0.86 | NR1H4 (0.43) | NR1H4CHRM3 | |
| SCHEMBL4523723 | 0.86 | ALDH1A1 (0.42) | NR1H4TLR9TLR8TLR7GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203577-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203577-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | NR1H4, NR1I2, GPBAR1 | HRH4 409/4885NR1H4 1/4885TLR9 3605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.